Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV

20253 citationsJournal Article

Authors

Debbie Hagins · Coastal Health District

Mezgebe Berhe · Infectious Disease Consultants

Gordon Crofoot

Moti Ramgopal · Midway University

James J. Sims · St. Hope Foundation

Cheryl McDonald · Texas Center for Infectious Disease

Peter Ruane · Ruane Medical

Abstract

Lenacapavir-containing combinations achieved and maintained high rates of virologic suppression in treatment-naive participants through W132; lenacapavir was well tolerated. These data support future development of lenacapavir-containing regimens for HIV-1 treatment.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV-related health complications and treatments

Publication Details

Published in: AIDS

Volume 40, Issue 3, pp. 302-311

DOI: 10.1097/qad.0000000000004372

Field-Weighted Citation Impact: 4.78

Command Palette

Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV

Authors

Abstract

Topics & Keywords

Publication Details